retatrutide clinical trials netherlands Retatrutide, the next generation of GLP-1 drug from Eli Lilly, helped participants lose an average of 71.2 pounds and reduce knee arthritis pain in a late-stage trial, the company announced Retatrutide: Phase 3 Results (Up

Abstract Cardiovascular disease (CVD) remains the leading cause of death in patients with type 2 diabetes (T2D)

These rats were less motivated to survive in a forced swim test [52]

Increase the risk of sagging skin , as rapid weight loss can leave the skin without the underlying support needed to maintain its elasticity, and may not be able to keep up with the reduction in volume underneath

Wunsch and Matuschka 2014 in Photomedicine and Laser Surgery (32(2):93-100, PMC3926176) documented statistically significant improvements in skin complexion, fine lines, wrinkles, skin roughness, and intradermal collagen density in subjects treated with red and near-infrared light

For more detail about the 2024 survey, see the Survey Methodology section of that years report

While this seems to be a major downside of the company, its not actually as bad as you might think